NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free SCYX Stock Alerts $1.47 -0.03 (-2.00%) (As of 03:32 PM ET) Add Compare Share Share Today's Range$1.42▼$1.4950-Day Range$1.39▼$1.8052-Week Range$1.35▼$3.87Volume81,122 shsAverage Volume197,399 shsMarket Capitalization$55.49 millionP/E Ratio1.11Dividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get SCYNEXIS alerts: Email Address SCYNEXIS MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside941.7% Upside$15.00 Price TargetShort InterestBearish2.75% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.08) to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector429th out of 907 stocksPharmaceutical Preparations Industry193rd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSCYNEXIS has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.75% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in SCYNEXIS has recently increased by 6.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCYX. Previous Next 2.0 News and Social Media Coverage News SentimentSCYNEXIS has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for SCYNEXIS this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for SCYX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to decrease in the coming year, from ($0.08) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is 1.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.00.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is 1.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 194.35.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About SCYNEXIS Stock (NASDAQ:SCYX)SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More SCYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCYX Stock News HeadlinesApril 20, 2024 | finance.yahoo.comSCYNEXIS, Inc. (SCYX)April 20, 2024 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Share Price Crosses Below 200 Day Moving Average of $1.78April 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline ProspectsApril 9, 2024 | globenewswire.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)March 29, 2024 | msn.comSCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023March 28, 2024 | stockhouse.comSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 21, 2024 | benzinga.comSCYNEXIS Stock (NASDAQ:SCYX) Insider TradesFebruary 1, 2024 | markets.businessinsider.comPromising Antifungal Drug Developments Bolster Buy Rating for SCYNEXISJanuary 30, 2024 | finance.yahoo.comSCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology ConferenceJanuary 30, 2024 | finance.yahoo.comSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis ConferenceJanuary 8, 2024 | stockhouse.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmJanuary 6, 2024 | markets.businessinsider.comScynexis 48 Hour Deadline AlertJanuary 5, 2024 | finance.yahoo.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, ItalyJanuary 1, 2024 | markets.businessinsider.comSCYX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYXDecember 29, 2023 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmDecember 29, 2023 | barrons.comFINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the FirmDecember 26, 2023 | stockhouse.comScynexis Deadline ReminderDecember 25, 2023 | markets.businessinsider.comTOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYXDecember 23, 2023 | stockhouse.comSCYNEXIS, Inc. (SCYX) Securities Fraud: Contact Berger Montague To Discuss Your RightsDecember 22, 2023 | morningstar.comSCYNEXIS Inc SCYXDecember 21, 2023 | stockhouse.comDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmDecember 18, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of SCYNEXIS, Inc. (SCYX)December 17, 2023 | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmDecember 17, 2023 | markets.businessinsider.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYXSee More Headlines Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+900.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.32 Trailing P/E Ratio1.14 Forward P/E RatioN/A P/E GrowthN/ANet Income$67.04 million Net Margins47.84% Pretax Margin47.94% Return on Equity156.27% Return on Assets71.00% Debt Debt-to-Equity Ratio0.17 Current Ratio6.26 Quick Ratio6.26 Sales & Book Value Annual Sales$140.14 million Price / Sales0.40 Cash Flow$1.97 per share Price / Cash Flow0.76 Book Value$1.96 per share Price / Book0.77Miscellaneous Outstanding Shares37,753,000Free Float36,092,000Market Cap$56.63 million OptionableOptionable Beta1.57 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David Gonzalez Angulo M.D. (Age 59)CEO, President & Director Comp: $631.69kMr. Scott Sukenick J.D. (Age 46)Chief Legal Officer & Corporate Secretary Comp: $542.05kMr. Ivor Macleod CPA (Age 63)M.B.A., Chief Financial Officer Debbie EtchisonExecutive Director of CommunicationsMs. Daniella GiganteVice President of Human Resources & Information TechnologyKey CompetitorsKronos BioNASDAQ:KRONKezar Life SciencesNASDAQ:KZREquilliumNASDAQ:EQHCW BiologicsNASDAQ:HCWBImmix BiopharmaNASDAQ:IMMXView All CompetitorsInstitutional OwnershipSimplicity Wealth LLCBought 20,000 shares on 4/24/2024Ownership: 0.053%Kingdon Capital Management L.L.C.Bought 359,900 shares on 3/18/2024Ownership: 6.012%Avidity Partners Management LPBought 129,284 shares on 2/14/2024Ownership: 3.893%Stonepine Capital Management LLCSold 1,497,413 shares on 2/13/2024Ownership: 3.642%Decheng Capital LLCBought 555,555 shares on 2/12/2024Ownership: 1.493%View All Institutional Transactions SCYX Stock Analysis - Frequently Asked Questions Should I buy or sell SCYNEXIS stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares. View SCYX analyst ratings or view top-rated stocks. What is SCYNEXIS's stock price target for 2024? 1 brokers have issued 12 month price objectives for SCYNEXIS's shares. Their SCYX share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price. View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts. How have SCYX shares performed in 2024? SCYNEXIS's stock was trading at $2.23 at the beginning of 2024. Since then, SCYX shares have decreased by 35.4% and is now trading at $1.44. View the best growth stocks for 2024 here. When is SCYNEXIS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SCYX earnings forecast. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.73. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.50 million. SCYNEXIS had a net margin of 47.84% and a trailing twelve-month return on equity of 156.27%. During the same period in the prior year, the company posted ($0.28) earnings per share. When did SCYNEXIS's stock split? SCYNEXIS shares reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS). Who are SCYNEXIS's major shareholders? SCYNEXIS's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Simplicity Wealth LLC (0.05%). Insiders that own company stock include Marco Taglietti and Scott Sukenick. View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCYX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
